B cell immunotherapy has emerged as a mainstay in the treatment of lymphomas and
autoimmune diseases. Although the microenvironment has recently been demonstrated to …

Apolipoprotein (apo) E4 is a major risk factor for Alzheimer's disease, and many studies
have suggested that apoE has isoform-specific effects on the deposition or clearance of …

Alzheimer's disease is a progressive neurodegenerative disease characterized by senile
plaques, neurofibrillary tangles, dystrophic neurites, and reactive glial cells. Activated …

As indicated by its name, V-domain Ig suppressor of T cell activation (VISTA) is thought to
serve primarily as an inhibitory protein that limits immune responses. VISTA antibodies can …

Background CD40 agonist immunotherapy can potentially license antigen-presenting cells
to promote antitumor T-cell activation and re-educate macrophages to destroy tumor stroma …

Agonistic CD40 monoclonal antibodies (mAb) have demonstrated some clinical activity, but
with dose-limiting toxicity. To reduce systemic toxicity, we developed a bispecific molecule …

Removal of pathogenic B lymphocytes by depletion of monoclonal antibodies (mAbs) or
deprivation of B-cell survival factors has demonstrated clinical benefit in both oncologic and …

Background The receptor for the cytokine TWEAK (TweakR) is a cell surface member of the
tumor necrosis factor receptor superfamily with diverse biological roles. TNFRSF family …

The development of immune checkpoint–based immunotherapies has been a major
advancement in the treatment of cancer, with a subset of patients exhibiting durable clinical …

Introduction Targeting the CD20 antigen has been a successful therapeutic intervention in
the treatment of rheumatoid arthritis (RA). However, in some patients with an inadequate …